Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals, Inc. (IONS) is a healthcare company (biotechnology) based in the United States. The share price is $27.01, down 3.58% on the day, which values the company at $4.5B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$27.01−3.58% today
Market value
$4.5B
Funk Score
34/100
Against its own history
Well below its usual priceusual price $40.90
200-week average
$48.9345% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Ionis Pharmaceuticals, Inc. in more detail

IONS trades at -13.3× next year's expected earnings, 4.7× sales. Measured against its own history, the price is 34% below what its usual multiples would imply ($40.90) — well below its usual price. It sits 45% below its 200-week average of $48.93.

Over the last five fiscal years Ionis Pharmaceuticals, Inc. has compounded revenue 5.3% a year. Its Funk Score is 34 out of 100 (financial strength 3.6, profitability 0.8, growth 6.1, value 3.1, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.

4 of the superinvestors tracked here hold IONS, including Tweedy, Browne team (6.5% of the portfolio), Julian and Felix Baker (0.8% of the portfolio), Cathie Wood (0.2% of the portfolio).

Superinvestors holding IONS

4 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:IONS vs LIVN (Ionis Pharmaceuticals, Inc. vs LivaNova)IONS vs DNTH (Ionis Pharmaceuticals, Inc. vs Dianthus Therapeutics)IONS vs MMED (Ionis Pharmaceuticals, Inc. vs MiniMed Group)IONS vs ADPT (Ionis Pharmaceuticals, Inc. vs Adaptive Biotechnologies)IONS vs EWTX (Ionis Pharmaceuticals, Inc. vs Edgewise Therapeutics)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Ionis Pharmaceuticals, Inc. (IONS): questions and answers

What is IONS's PEG ratio?

Ionis Pharmaceuticals, Inc.'s PEG ratio is 27.33 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Ionis Pharmaceuticals, Inc.'s market cap?

Ionis Pharmaceuticals, Inc. is valued at $4.5B at a share price of $27.01.

Is IONS overvalued or undervalued?

Against its own history, IONS is well below its usual price: the price is 34% below the $40.90 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is IONS above its 200-week moving average?

No. IONS is 44.8% below its 200-week average of $48.93. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Ionis Pharmaceuticals, Inc. growing?

Over the last five fiscal years Ionis Pharmaceuticals, Inc.'s revenue grew 5.3% a year; over ten years revenue grew 12.8% a year.

Does IONS pay a dividend?

Ionis Pharmaceuticals, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Ionis Pharmaceuticals, Inc. (IONS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IONS

Underlying data: Yahoo Finance; company filings with the SEC.